Clinical Trials on Recurrent Adult Acute Lymphoblastic Leukemia in China

Total 648 results

Shenzhen Geno-Immune Medical Institute
The Second Affiliated Hospital of Hainan Medical University; Beijing Jingdu...

Recruiting

Universal 4SCAR7U Targeting CD7-positive Malignancies

Acute Myeloid Leukemia | T-cell Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic Lymphoma | NK Cell Lymphoma

China
Shanghai Pudong Hospital
UTC Therapeutics Inc.

Withdrawn

Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies

Acute Myeloid Leukemia (AML) | Multiple Myeloma (MM) | B-cell Non-Hodgkin's Lymphoma (B-NHL) | T-Cell Leukemia/Lymphoma, Adult | B-cell Acute Lymphoblastic Leukemia (B-ALL)

China
Shanghai Unicar-Therapy Bio-medicine Technology...
The First Affiliated Hospital of Soochow University

Recruiting

Clinical Study of ssCART-19 Cells in Patients With CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia

Relapsed or Refractory Acute Lymphoblastic Leukemia

China
Essen Biotech

Not yet recruiting

Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). (BAH241)

Lymphoma, Follicular | Diffuse Large B Cell Lymphoma | Acute Lymphoblastic Leukemia, in Relapse | MCL | Central Nervous System Lymphoma | Acute Lymphoblastic Leukemia, Adult B-Cell | Non-Hodgkin Lymphoma, B-cell

China
Peking University People's Hospital
Cellular Biomedicine Group Ltd.

Unknown

C-CAR011 Treatment in Subjects With ALL After HSCT

Acute Lymphoblastic Leukemia(ALL)

China
Min Xiang

Unknown

RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL

T-lymphoblastic Lymphoma | T Acute Lymphoblastic Leukemia

China
920th Hospital of Joint Logistics Support Force...

Withdrawn

A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL

T-lymphoblastic Lymphoma | T-cell Acute Lymphoblastic Leukemia

China
Xuanwu Hospital, Beijing
Baoding Children's Hospital

Recruiting

CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia

T-cell Acute Lymphoblastic Leukemia

China
Anhui Provincial Hospital

Recruiting

QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

B-cell Acute Lymphoblastic Leukemia

China
The First Affiliated Hospital of Soochow University
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical... and other collaborators

Recruiting

Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL

B-cell Acute Lymphoblastic Leukemia

China
The First Affiliated Hospital of Nanchang University

Unknown

Anti-CD19 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphomas

Acute Lymphoblastic Leukemia ,Lymphomas

China
Tianjin Mycure Medical Technology Co., Ltd

Unknown

CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.

B-cell Acute Lymphoblastic Leukemia

China
Henan Cancer Hospital
The Beijing Pregene Science and Technology Company, Ltd.

Unknown

The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).

B-cell Acute Lymphoblastic Leukemia

China
Tongji Hospital

Unknown

Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients (TCLDCWTTNDPP)

ph+ Acute Lymphoblastic Leukemia

China
Sun Yat-sen University

Unknown

The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

China
Wei Zhao
Qilu Hospital of Shandong University; The Affiliated Hospital of Qingdao University and other collaborators

Not yet recruiting

The Individualized Treatment of 6-mercaptopurine in Children With Acute Lymphoblastic Leukemia in China

Acute Lymphoblastic Leukemia, Pediatric

China
Prince of Wales Hospital, Shatin, Hong Kong

Completed

Two Combination Chemotherapy Regimens in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia

Leukemia

China
The First Affiliated Hospital of Soochow University
Northern Jiangsu Province People's Hospital; The Second People's Hospital of... and other collaborators

Recruiting

Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients

Recruiting | T-cell Acute Lymphoblastic Leukemia

China
Juventas Cell Therapy Ltd.

Completed

A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia

Relapsed or Refractory Acute Lymphoblastic Leukemia

China
The First Affiliated Hospital of Soochow University
Northern Jiangsu Province People's Hospital; The Second People's Hospital of... and other collaborators

Recruiting

CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL

B-cell Acute Lymphoblastic Leukemia

China
Shenzhen Geno-Immune Medical Institute

Recruiting

NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL

B-Cell Acute Lymphoblastic Leukemia

China
Bioceltech Therapeutics, Ltd.

Unknown

CD19-CAR-T Cells in Patients With R/R B-ALL

B-cell Acute Lymphoblastic Leukemia

China
Xijing Hospital

Recruiting

Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-naïve Ph+ Acute Lymphoblastic Leukemia

Newly-diagnosed Ph+ Acute Lymphoblastic Leukemia

China
Hrain Biotechnology Co., Ltd.
Second Affiliated Hospital of Nanchang University

Recruiting

To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL

B-cell Acute Lymphoblastic Leukemia

China
The First Affiliated Hospital of Soochow University

Recruiting

Study of IFN-α Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia（R/R-ALL）

B-cell Acute Lymphoblastic Leukemia

China
The First Affiliated Hospital of Soochow University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Recruiting

CAR-T Cell Therapy Targeting to CD19 for R/R ALL

Acute Lymphoblastic Leukemia With Failed Remission

China
Harbin Hematology and Oncology Institute

Completed

Evaluate the Hematological Remission Rates and Survival Among Chinese Adult Patients With B-precursor ALL (BLING)

B-precursor Acute Lymphoblastic Leukemia

China
Shanghai Unicar-Therapy Bio-medicine Technology...
Peking University People's Hospital; The First Affiliated Hospital of Soochow...

Not yet recruiting

Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration)

Relapsed or Refractory Acute Lymphoblastic Leukemia

China
Kunming Hope of Health Hospital

Withdrawn

Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL

B-cell Acute Lymphoblastic Leukemia | B-ALL

China
Chongqing Precision Biotech Co., Ltd

Completed

Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents

Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Relapsed Pediatric ALL

China
Fundamenta Therapeutics, Ltd.
The First Affiliated Hospital of University of Science and Technology of...

Recruiting

Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies

T-Acute Lymphoblastic Leukemia | T-cell Non-Hodgkin Lymphoma | T-cell Acute Lymphoblastic Lymphoma

China
Institute of Hematology & Blood Diseases Hospital
Juventas Cell Therapy Ltd.

Active, not recruiting

CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)

Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia

China
Shenzhen BinDeBio Ltd.
The First Affiliated Hospital of Zhengzhou University

Unknown

A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects

Refractory B-cell Acute Lymphoblastic Leukemia | Relapsed B-cell Acute Lymphoblastic Leukemia | Relapsed／Refractory B-cell Lymphoma

China
Nanfang Hospital, Southern Medical University

Recruiting

A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL (ABC)

Acute Lymphoblastic Leukemia | Philadelphia Chromosome | Adult ALL | Philadelphia-Positive ALL | IKZF1 Gene Mutation

China
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia

Acute Lymphocytic Leukemia

China
Cellular Biomedicine Group Ltd.
Chinese PLA General Hospital

Unknown

A Phase I Study Evaluating Safety and Efficacy of C-CAR011 Treatment in Adult Subjects With r/r CD19+B-ALL

Relapsed or Refractory Acute Lymphoblastic Leukemia

China
920th Hospital of Joint Logistics Support Force...

Recruiting

Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL

B-cell Acute Lymphoblastic Leukemia | B-ALL

China
The First Affiliated Hospital of Soochow University

Not yet recruiting

Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL

B-cell Acute Lymphoblastic Leukemia

China
wang, jianxiang

Not yet recruiting

Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage

Acute Leukemia of Ambiguous Lineage

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies

Acute Lymphoblastic Leukemia, in Relapse | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory | Acute Lymphocytic Leukaemia Refractory

China
The Affiliated Hospital of Xuzhou Medical University

Recruiting

Clinical Study of Anti-CD1a CAR-T in the Treatment of R/R Acute T-lymphoblastic Leukemia/Lymphoblastic Lymphoma

Acute T-lymphoblastic Leukemia | Acute T-lymphoblastic Lymphoma

China
Chen Suning

Completed

Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL

B Acute Lymphoblastic Leukemia

China
Chinese PLA General Hospital

Unknown

A Feasibility and Safety Study of CD38 CAR-T Cell Immunotherapy for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy

Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T ACI

China
Nanfang Hospital of Southern Medical University

Recruiting

Induced-T Cell Like NK Cells for B Cell Malignancies

B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia | B Cell Leukemia | B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.

Recruiting

Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances

T-cell Acute Lymphoblastic Leukemia | T-cell Non-Hodgkin Lymphoma | T-cell Acute Lymphoblastic Lymphoma

China
Chinese PLA General Hospital

Unknown

Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33 (CART33)

Relapsed Adult Myeloid Leukemia | Chemotherapy Refractory Adult Myeloid Leukemia

China
CytoCares Inc

Recruiting

Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies

Chronic Lymphocytic Leukemia | Non-hodgkin Lymphoma | Acute Lymphoblastic Leukaemia

China
Anhui Provincial Hospital
Leman Biotech Co., Ltd

Recruiting

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical Research

B-cell Acute Lymphoblastic Leukemia

China
Hebei Yanda Ludaopei Hospital
Gracell Biotechnology Ltd.; Beijing Lu Daopei Hospital

Unknown

A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL

B-cell Acute Lymphoblastic Leukemia

China
Hebei Yanda Ludaopei Hospital
Gracell Biotechnology Ltd.

Unknown

A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL

B-cell Acute Lymphoblastic Leukemia

China

Clinical Trials on Recurrent Adult Acute Lymphoblastic Leukemia in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations